Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Network meta-analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • الموضوع:
      2025
    • نبذة مختصرة :
      Introduction Osteoarthritis (OA) as a degenerative disease, has seen a continuous rise in incidence and prevalence globally since 1990, imposing a significant disease burden. NSAIDs (Nonsteroidal anti-inflammatory drugs) as symptomatic medications for OA treatment, hold an indispensable position in clinical practice. Objective To evaluate the efficacy and safety of different NSAIDs in the treatment of OA through Bayesian Network Meta-Analysis (NMA). Methods Randomized controlled trials (RCTs) on NSAIDs for OA treatment were retrieved from PubMed, Web of Science, Embase, and the Cochrane Library databases. The search timeframe was from the inception of each database up to June 1, 2024. Outcome indicators for NMA were all conducted using a random-effects model. MetaInsight and Stata 14.0 software were used in R for calculations and plotting of NMA. Measurement data were represented by mean difference (MD), and count data by odds ratio (OR); a 95% confidence interval (CI) was also calculated for each effect size. Results This study included 31 studies, involving 68,539 patients with knee osteoarthritis (KOA) and 16 interventions. NMA results showed that compared to the placebo, Tiaprofenic reduced the VAS score (MD = -0.16, 95% CI: (-0.46 to 0.14), P > 0.05), albeit without significant difference; meanwhile, Diclofenac reduced the total WOMAC score in KOA patients (MD = -0.41, 95% CI: -1.05 to 0.24, P > 0.05). Compared to the placebo, Etoricoxib was the best medication for improving the WOMAC pain subscale score (MD = -0.44; 95% CI: -0.61 to -0.26); Naproxen significantly improved the WOMAC Function score in KOA patients after administration (MD = -0.43; 95% CI: -0.82 to -0.04); Diclofenac intervention significantly reduced the WOMAC Stiffness score in KOA patients (MD = -0.40; 95% CI: -0.67 to -0.13). In terms of adverse event rates, compared to the placebo, the use of Etoricoxib significantly increased the incidence of cardiovascular adverse events (OR = 0.56, 95% CI: 0.32–0.99); Ketoprofen had fewer ...
    • الرقم المعرف:
      10.1371/journal.pone.0320379.g005
    • الدخول الالكتروني :
      https://doi.org/10.1371/journal.pone.0320379.g005
      https://figshare.com/articles/figure/Network_meta-analysis_/28947470
    • Rights:
      CC BY 4.0
    • الرقم المعرف:
      edsbas.F723EC82